Miriam O Ezenwa1, Robert E Molokie2, Zaijie Jim Wang3, Yingwei Yao1, Marie L Suarez4, Brenda Dyal1, Khulud Abudawood1, Diana J Wilkie5. 1. Department of Biobehavioral Nursing Science, College of Nursing, University of Florida, Gainesville, Florida. 2. College of Medicine, College of Pharmacy, and Comprehensive Sickle Cell Center, University of Illinois, Chicago, Illinois; Jesse Brown VA Medical Center, Chicago, Illinois. 3. Department of Biopharmaceutical Sciences, Cancer Center and Comprehensive Sickle Cell Center, University of Illinois, Chicago, Illinois. 4. Department of Biobehavioral Health Science (MC 802), University of Illinois at Chicago, College of Nursing, Chicago, Illinois. 5. Department of Biobehavioral Nursing Science, College of Nursing, University of Florida, Gainesville, Florida. Electronic address: diwilkie@ufl.edu.
Abstract
BACKGROUND: Patients with sickle cell disease (SCD) report pain scores that appear greater than those reported in a meta-analysis for patients with cancer, but statistical comparisons of the pain scores from both populations have not been published. AIMS: The goal of the study described here was to compare pain outcomes reported by outpatients with cancer or SCD. DESIGN: Descriptive comparative study. SETTING: Outpatient oncology or sickle cell clinics. SUBJECTS: The participants were outpatients (N = 415) from three studies: (1) 106 patients with SCD, 93% African-American (referent group); (2) 140 patients with cancer, 90% Caucasian (race discordant); (3) 169 patients with cancer, 20% Caucasian, 65% African-American (race concordant). METHODS: Patients completed the PAINReportIt including pain location, quality, pattern, intensity, expectation, satisfaction, and demographic questions. Analyses included the χ2 test, analysis of variance, and regression. RESULTS: Outpatients with SCD reported more pain location sites than the race-discordant (p < .001) and race-concordant (p < .001) cancer groups; higher pain quality than the race-discordant (p < .001) and race-concordant (p < .001) groups; and greater pain pattern scores than the race-discordant (p < .001) and race-concordant (p < .001) groups. The race-concordant group reported higher worst pain intensity than the SCD (p < .001) and race-discordant (p = .002) groups. The three groups did not differ significantly on pain expectation (p = .06). Regarding satisfaction with pain level, there was a significant difference between the race-concordant and SCD (p = .006) groups, but not between the race-discordant and SCD (p = .12) groups or between the race-discordant and race-concordant (p = .49) groups. CONCLUSIONS: Outpatients with SCD reported three of four sensory pain parameters that were greater than those reported by outpatients with cancer. A better understanding of these differences is pertinent to improving pain outcomes.
BACKGROUND:Patients with sickle cell disease (SCD) report pain scores that appear greater than those reported in a meta-analysis for patients with cancer, but statistical comparisons of the pain scores from both populations have not been published. AIMS: The goal of the study described here was to compare pain outcomes reported by outpatients with cancer or SCD. DESIGN: Descriptive comparative study. SETTING:Outpatient oncology or sickle cell clinics. SUBJECTS: The participants were outpatients (N = 415) from three studies: (1) 106 patients with SCD, 93% African-American (referent group); (2) 140 patients with cancer, 90% Caucasian (race discordant); (3) 169 patients with cancer, 20% Caucasian, 65% African-American (race concordant). METHODS:Patients completed the PAINReportIt including pain location, quality, pattern, intensity, expectation, satisfaction, and demographic questions. Analyses included the χ2 test, analysis of variance, and regression. RESULTS: Outpatients with SCD reported more pain location sites than the race-discordant (p < .001) and race-concordant (p < .001) cancer groups; higher pain quality than the race-discordant (p < .001) and race-concordant (p < .001) groups; and greater pain pattern scores than the race-discordant (p < .001) and race-concordant (p < .001) groups. The race-concordant group reported higher worst pain intensity than the SCD (p < .001) and race-discordant (p = .002) groups. The three groups did not differ significantly on pain expectation (p = .06). Regarding satisfaction with pain level, there was a significant difference between the race-concordant and SCD (p = .006) groups, but not between the race-discordant and SCD (p = .12) groups or between the race-discordant and race-concordant (p = .49) groups. CONCLUSIONS: Outpatients with SCD reported three of four sensory pain parameters that were greater than those reported by outpatients with cancer. A better understanding of these differences is pertinent to improving pain outcomes.
Authors: Hussain R Yusuf; Hani K Atrash; Scott D Grosse; Christopher S Parker; Althea M Grant Journal: Am J Prev Med Date: 2010-04 Impact factor: 5.043
Authors: Claudia M Campbell; Gyasi Moscou-Jackson; C Patrick Carroll; Kasey Kiley; Carlton Haywood; Sophie Lanzkron; Matthew Hand; Robert R Edwards; Jennifer A Haythornthwaite Journal: J Pain Date: 2016-02-16 Impact factor: 5.820
Authors: Carlton Haywood; Marie Diener-West; John Strouse; C Patrick Carroll; Shawn Bediako; Sophie Lanzkron; Jennifer Haythornthwaite; Gladys Onojobi; Mary Catherine Beach Journal: J Pain Symptom Manage Date: 2014-04-15 Impact factor: 3.612
Authors: Lauren N Whiteman; Carlton Haywood; Sophie Lanzkron; John J Strouse; Leonard Feldman; Rosalyn W Stewart Journal: South Med J Date: 2015-09 Impact factor: 0.954
Authors: Mary C White; Dawn M Holman; Jennifer E Boehm; Lucy A Peipins; Melissa Grossman; S Jane Henley Journal: Am J Prev Med Date: 2014-03 Impact factor: 5.043
Authors: Miriam O Ezenwa; Yingwei Yao; Christopher G Engeland; Robert E Molokie; Zaijie Jim Wang; Marie L Suarez; Diana J Wilkie Journal: J Adv Nurs Date: 2016-01-15 Impact factor: 3.187